美股異動 | 艾伯森(ACI.US)跌5.65% 2022財年指引低於市場預期 公司警吿成本上升和勞動力短缺
格隆匯4月12日丨艾伯森(ACI.US)跌5.65%,報32.815美元。公司公佈2021年第四財季業績,截至2月26日的三個月裏,公司實現Q4淨利潤4.551億美元,而去年同期則虧損1.442億美元。每股收益為79美分,上年同期為虧損37美分;營收從上年同期的157.7億美元攀升至173.8億美元。公司警吿,成本上升和勞動力短缺正在給運營帶來壓力,未來可能會帶來更多風險。公司預計2022財年每股收益在2.70美元至2.85美元之間,該區間的中點低於每股2.81美元的市場預期。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.